Technical Analysis for PIRS - Pieris Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 3.87 0.78% 0.03
PIRS closed up 0.78 percent on Friday, November 15, 2019, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical PIRS trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Death Cross Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
200 DMA Resistance Bearish 0.78%

Older signals for PIRS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Medicine Chemistry Cancers Dialysis Membrane Technology Asthma Chronic Kidney Disease Anatomy Inflammatory Diseases End Stage Renal Disease Kidney Diseases Hepatology Kidney Hepcidin Treatment Of Various Types Of Cancers
Is PIRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.04
52 Week Low 2.39
Average Volume 791,178
200-Day Moving Average 3.8952
50-Day Moving Average 3.8836
20-Day Moving Average 3.5225
10-Day Moving Average 3.814
Average True Range 0.3548
ADX 21.84
+DI 20.893
-DI 14.6829
Chandelier Exit (Long, 3 ATRs ) 3.1856
Chandelier Exit (Short, 3 ATRs ) 4.0344
Upper Bollinger Band 4.1742
Lower Bollinger Band 2.8708
Percent B (%b) 0.77
BandWidth 37.002129
MACD Line 0.0518
MACD Signal Line -0.0108
MACD Histogram 0.0625
Fundamentals Value
Market Cap 171.47 Million
Num Shares 44.3 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -5.45
Price-to-Sales 31.97
Price-to-Book 22.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.08
Resistance 3 (R3) 4.08 4.02 4.05
Resistance 2 (R2) 4.02 3.96 4.02 4.03
Resistance 1 (R1) 3.94 3.93 3.91 3.94 4.02
Pivot Point 3.88 3.88 3.86 3.88 3.88
Support 1 (S1) 3.80 3.82 3.77 3.80 3.72
Support 2 (S2) 3.74 3.79 3.74 3.71
Support 3 (S3) 3.66 3.74 3.70
Support 4 (S4) 3.66